SIPA1L3 and neoplasm: Given the absence of a second TSC2 variant, TSC2-LOH or any other evident tumor driver apart from the unclear variant in SIPA1L3 in the renal and hepatic AMLs of the herewith reported individual, a contribution of the germline ARID1B variant to the tumorigenesis cannot be excluded.